: The escalation of antimicrobial resistance, especially among ESKAPE pathogens, calls for new antibacterial agents with improved effectiveness against bacteria often causing difficult-to-treat infections. In this work, two sets of carbazole derivatives were designed and evaluated against a broad panel of both reference strains and resistant clinical isolates. In the first set, chlorinated compounds showed superior antibacterial performance compared with non-halogenated analogues. The addition of cationic or chelating functionalities (e.g., 4e, 4f, 6b, and 7b) further increased activity against Gram-negative species even without colistin, suggesting improved interaction with or penetration through the outer membrane. Compounds 6b and 7b were particularly effective against multidrug-resistant isolates, with no apparent cross-resistance. The second set did not display a clear dependence on halogen substitution; however, piperazino-substituted derivatives (23a-d) showed selective activity against Gram-positive bacteria and resistant isolates, which was strongly enhanced, on Gram-negatives, by subinhibitory concentrations of colistin. A three-parameter physicochemical analysis integrating lipophilicity, polar surface area, and dipole moment distinguished active from inactive molecules and implicated membrane disruption as the underlying mechanism, a finding further supported by propidium iodide uptake experiments. Overall, carbazole derivatives represent promising candidates for the development of new antibacterial agents targeting resistant pathogens.

Synthesis and biological evaluation of novel carbazole derivatives as broad-spectrum antibacterial agents to fight antimicrobial resistance (AMR) / Martina, M.G., Barbieri, F., Cancade, S.M.I., Benocci, G., Chittolina, A., Longo, M., Giannessi, L., Rossi, S., Gemma, S., Campiani, G., Docquier, J.-D., Radi, M.. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - 224:(2026). [10.1016/j.ejps.2026.107595]

Synthesis and biological evaluation of novel carbazole derivatives as broad-spectrum antibacterial agents to fight antimicrobial resistance (AMR)

Martina M. G.;Giannessi L.;Radi M.
2026-01-01

Abstract

: The escalation of antimicrobial resistance, especially among ESKAPE pathogens, calls for new antibacterial agents with improved effectiveness against bacteria often causing difficult-to-treat infections. In this work, two sets of carbazole derivatives were designed and evaluated against a broad panel of both reference strains and resistant clinical isolates. In the first set, chlorinated compounds showed superior antibacterial performance compared with non-halogenated analogues. The addition of cationic or chelating functionalities (e.g., 4e, 4f, 6b, and 7b) further increased activity against Gram-negative species even without colistin, suggesting improved interaction with or penetration through the outer membrane. Compounds 6b and 7b were particularly effective against multidrug-resistant isolates, with no apparent cross-resistance. The second set did not display a clear dependence on halogen substitution; however, piperazino-substituted derivatives (23a-d) showed selective activity against Gram-positive bacteria and resistant isolates, which was strongly enhanced, on Gram-negatives, by subinhibitory concentrations of colistin. A three-parameter physicochemical analysis integrating lipophilicity, polar surface area, and dipole moment distinguished active from inactive molecules and implicated membrane disruption as the underlying mechanism, a finding further supported by propidium iodide uptake experiments. Overall, carbazole derivatives represent promising candidates for the development of new antibacterial agents targeting resistant pathogens.
2026
Synthesis and biological evaluation of novel carbazole derivatives as broad-spectrum antibacterial agents to fight antimicrobial resistance (AMR) / Martina, M.G., Barbieri, F., Cancade, S.M.I., Benocci, G., Chittolina, A., Longo, M., Giannessi, L., Rossi, S., Gemma, S., Campiani, G., Docquier, J.-D., Radi, M.. - In: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. - ISSN 0928-0987. - 224:(2026). [10.1016/j.ejps.2026.107595]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/3075397
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact